Key Takeaways Biogen posted Q3 EPS of $4.81, up 18$2.53B in revenue.New drugs Leqembi, Skyclarys and Zurzuvae drove 67% growth in launch product sales.Despite lifting sales guidance, Biogen trimmed its 2025 EPS view to $14.50-$15.00 due to deal costs.Biogen (BIIB) reported third-quarter 2025 adjusted earnings per share (EPS) of $4.81, which beat the Zacks Consensus Estimate of$3.89. Earnings rose 18% year over year.Total revenues during the quarter came in at $2.53 ...